QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, September 16, 2009, 29(37):11550-11559; doi:10.1523/JNEUROSCI.3307-09.2009

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in J. Neurosci. Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dai, Y. Articles by Muma, N. A. Search for Related Content PubMed PubMed Citation Articles by Dai, Y. Articles by Muma, N. A.

 Previous Article  |  Next Article 

Neurobiology of Disease
Striatal Expression of a Calmodulin Fragment Improved Motor Function, Weight Loss, and Neuropathology in the R6/2 Mouse Model of Huntington's Disease

Ying Dai,^1,3 Nichole L. Dudek,² Qian Li,³ Stephen C. Fowler,³ and Nancy A. Muma³

¹Neuroscience Graduate Program, Loyola University Medical Center, and ²Department of Pharmacology and Experimental Therapeutics, Loyola University Chicago, School of Medicine, Maywood, Illinois 60153, and ³Department of Pharmacology and Toxicology, University of Kansas, School of Pharmacy, Lawrence, Kansas 66045

Correspondence should be addressed to Nancy A. Muma, Department of Pharmacology and Toxicology, University of Kansas, 1251 Wescoe Hall Drive, 5064 Malott Hall, Lawrence, KS 66045. Email: nmuma{at}ku.edu

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a polyglutamine expansion in the huntingtin protein (htt). Increasing evidence suggests that transglutaminase (TGase) plays a critical role in the pathophysiology of HD possibly by stabilizing monomeric, polymeric and aggregated htt. We previously reported that in HEK293 and SH-SY5Y cells expression of a calmodulin (CaM)-fragment, consisting of amino acids 76-121 of CaM, decreased binding of CaM to mutant htt, TGase-modified htt and cytotoxicity associated with mutant htt and normalized intracellular calcium release. In this study, an adeno-associated virus (AAV) that expresses the CaM-fragment was injected into the striatum of HD transgenic R6/2 mice. The CaM-fragment significantly reduced body weight loss and improved motor function as indicated by improved rotarod performance, longer stride length, lower stride frequency, fewer low mobility bouts and longer travel distance than HD controls. A small but insignificant increase in survival was observed in R6/2 mice with CaM-fragment expression. Immunoprecipitation studies show that expression of the CaM-fragment reduced TGase-modified htt in the striatum of R6/2 mice. The percentage of htt-positive nuclei and the size of intranuclear htt aggregates were reduced by the CaM-fragment without striatal volume changes. The effects of CaM-fragment appear to be selective, as activity of another CaM-dependent enzyme, CaM-dependent kinase II, was not altered. Moreover, inhibition of TGase-modified htt was substrate-specific since overall TGase activity in the striatum was not altered by treatment with the CaM-fragment. Together, these results suggest that disrupting CaM–htt interaction may provide a new therapeutic strategy for HD.

---

Received July 10, 2009; revised Aug. 6, 2009; accepted Aug. 11, 2009.

Correspondence should be addressed to Nancy A. Muma, Department of Pharmacology and Toxicology, University of Kansas, 1251 Wescoe Hall Drive, 5064 Malott Hall, Lawrence, KS 66045. Email: nmuma{at}ku.edu

Related articles in J. Neurosci.:

This Week in The Journal

J. Neurosci. 2009 29: i. [Full Text]  

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help